- The U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response's Biomedical Advanced Research and Development Authority (BARDA) awards a two-year $19.7M contract to Emergent Biosystems (NYSE:EBS) to develop and manufacture cGMP (current good manufacturing practice) lots of three Ebola monoclonal antibodies in CHO (Chinese hamster ovary) cell lines at a scale of 2,000 liters.
- Under the scope of the contract, Emergent will conduct process development, analytical method development, execute small scale production runs and perform cGMP cell banking leading to cGMP manufacture of bulk lots.
- The contract is the first BARDA Task Order for an Ebola countermeasure awarded to the company under the Center for Innovation in Advanced Development and Manufacturing Program (CIADM).